Obesity is a chronic disease — and biology is most of the answer

How obesity is defined and diagnosed

The medical diagnosis of obesity is made when body mass index (BMI) — weight in kilograms divided by height in meters squared — reaches 30 kg/m² or higher. Class I obesity is BMI 30–34.9, class II is 35–39.9, and class III (sometimes called severe obesity) is 40 and above.

BMI is a population-level screening tool, not a body-fat measurement. Clinicians look beyond BMI when refining diagnosis and treatment intensity:

• Waist circumference over 40 inches (men) or 35 inches (women) suggests visceral fat — the metabolically active fat that drives most cardiovascular and metabolic risk.
• Weight-related conditions like type 2 diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, PCOS, and osteoarthritis lower the BMI threshold for medical treatment to 27.
• Body composition matters. Highly muscular individuals may have an elevated BMI without excess fat. Conversely, people with normal BMI can carry harmful visceral fat ("normal-weight obesity").

Why "eat less, move more" is incomplete

Obesity is not a failure of willpower. It is a regulated biological state. The body defends a "set point" for adipose tissue using a network of hormones — leptin, ghrelin, GLP-1, peptide YY, insulin — that report energy status to the hypothalamus and tune appetite, satiety, and metabolic rate accordingly.

When someone with obesity loses weight through diet, the body reads it as starvation:

• Leptin (the satiety hormone) drops, intensifying hunger.
• Ghrelin (the hunger hormone) rises and stays elevated for years after weight loss.
• Resting metabolic rate falls more than expected — sometimes 200–500 calories per day below predicted — and can stay suppressed long-term ("metabolic adaptation").
• Food cues in the environment trigger stronger reward responses in the brain.

This is why behavior alone produces an average 5–10% weight loss in the first 6 months that the body then aggressively defends. "Food noise" — the constant intrusive thoughts about eating — is the lived experience of these biological signals.

How GLP-1 medications changed first-line treatment

GLP-1 receptor agonists work on the same hormonal axis that defends weight. They mimic glucagon-like peptide-1, an incretin hormone normally released from the gut after eating. The result:

• Slowed gastric emptying, so meals stay satisfying longer.
• Increased satiety signaling in the hypothalamus and reward centers.
• Reduced "food noise" — many patients describe it as the volume turning down for the first time in years.
• Improved insulin sensitivity and glucose-stimulated insulin release.

In the STEP and SURMOUNT clinical trial programs, semaglutide 2.4 mg produced an average weight loss of about 15% of body weight at 68 weeks, and tirzepatide 15 mg produced about 22.5% at 72 weeks — figures previously only achievable with bariatric surgery.

For full medication detail, see our pages on compounded semaglutide and compounded tirzepatide.

When clinicians escalate from lifestyle to medication

Current AACE and Endocrine Society guidance supports pharmacotherapy when:

What weight loss treats — beyond the scale

5–10% sustained weight loss meaningfully changes cardiometabolic risk; 10–15% improves it dramatically; 15%+ approaches what bariatric surgery delivers.

• Type 2 diabetes: 10% weight loss can put early diabetes into remission for many patients.
• Cardiovascular risk: The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease.
• Sleep apnea: Tirzepatide reduced apnea-hypopnea index by ~25–29 events/hour in the SURMOUNT-OSA trial.
• Fatty liver (MASH): Significant reduction in liver fat and inflammation at 15%+ weight loss.
• Knee osteoarthritis pain: Semaglutide significantly reduced pain in the STEP-9 trial.

Why weight comes back — and how to keep it off

Discontinuation studies show that stopping GLP-1 medications without a maintenance plan leads to regain of approximately two-thirds of lost weight within a year. This is biology, not a "rebound." Once the medication leaves the system, the underlying hormonal signaling reverts.

Strategies that protect against regain:

• Maintenance dosing. Many patients stay on a lower maintenance dose long-term once their goal weight is reached.
• Protein and resistance training. Preserving lean mass is the single biggest determinant of metabolic rate. Aim for 1.0–1.6 g protein per kg body weight.
• Sleep, stress, and alcohol. All three influence the same hormonal axis. See our guide on GLP-1s and alcohol.
• A clinician you can keep talking to. Plateau, life events, and dose adjustments are the rule, not the exception. See breaking a plateau.

Frequently asked questions